secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2026-09-18T20:05:31+00:00
Accession:  0001193125-26-395517
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm issues $20M Series A convertible preferred stock to settle forbearance fees
--------------------------------------------------------------------------------

- Issued 20,000 shares of 0% Series A Convertible Perpetual Preferred, $1,000 liquidation preference each, on Sept 17, 2026.
- Convertible into common at $1.62/share; capped at 4,520,000 shares until stockholder consent, with cash settlement for excess.
- Preferred ranks senior to common; holders can force repurchase at $1,000 after Sept 17, 2029 or on fundamental changes.
- Company must seek stockholder approval by March 15, 2027; deferred cash settlement until then if conversion exceeds cap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/0001193125-26-395517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312526395517/d141487d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-395517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer